Form 4: Director Schmalz Granted Shares in Applied DNA Sciences

Applied DNA Sciences director Elizabeth M. Schmalz was granted 22,511 shares of common stock, vesting in 90 days.

Summary

• Elizabeth M. Schmalz, a director of Applied DNA Sciences Inc. (BNBX), acquired 22,511 shares of common stock.
• The transaction occurred on October 17, 2025, and was reported on October 20, 2025.
• The shares were acquired at a price of $0, indicating a grant, likely restricted stock units.
• These restricted stock units will vest 100% upon 90 days from the date of grant.
• Following this transaction, Ms. Schmalz directly beneficially owns 22,512 shares of common stock.

Sentiment

Score: 6

Explanation: Slightly positive as it indicates continued director engagement and alignment of interests through equity ownership, which is a routine and expected part of director compensation.

Positives

• Increased ownership by a director, aligning management interests with shareholders.
• The grant of restricted stock units serves as an incentive for long-term performance and retention of key personnel.

Negatives

• No direct negatives are identified from this routine insider transaction filing.

Risks

• No specific risks are detailed in this Form 4 filing, which primarily reports an insider transaction.

Future Outlook

The 22,511 restricted stock units granted to Director Elizabeth M. Schmalz are scheduled to vest 100% upon 90 days from the grant date of October 17, 2025.

Industry Context

Equity grants, such as restricted stock units, are a common form of compensation for directors and executives in publicly traded companies. This practice aims to align the interests of company leadership with those of shareholders by tying a portion of their compensation to the company's stock performance and long-term value creation.

Comparison to Industry Standards

• Director equity compensation, often in the form of restricted stock units or options, is a standard practice across various industries, including biotechnology and life sciences, where Applied DNA Sciences operates.
• The vesting period of 90 days is relatively short compared to typical multi-year vesting schedules for executive performance-based equity, but can be common for non-employee director annual grants.
• Companies like Illumina (ILMN) or Thermo Fisher Scientific (TMO) also utilize equity grants for their non-employee directors, though specific grant sizes and vesting terms vary based on company size, compensation philosophy, and director responsibilities.

Corporate Governance

Related Party Transactions

• The grant of 22,511 shares of common stock to Elizabeth M. Schmalz, a director, constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: Increased alignment of director's financial interests with shareholder value due to equity ownership.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• The 22,511 restricted stock units granted to Director Schmalz will vest 100% approximately 90 days from the grant date.

Key Dates

Keywords

Applied DNA Sciences, BNBX, Insider Transaction, Form 4, Director Compensation, Restricted Stock Units, Equity Grant, Elizabeth M Schmalz